Ontology type: schema:ScholarlyArticle
2018-04
AUTHORSJ. N. Jakobsen, T. Urup, K. Grunnet, A. Toft, M. D. Johansen, S. H. Poulsen, I. J. Christensen, A. Muhic, H. S. Poulsen
ABSTRACTThe combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125 mg/m2 and bevacizumab 10 mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p = 0.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p = 0.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3-4) compared to iri-bev (3.5% grade 3-4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist. More... »
PAGES439-446
http://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x
DOIhttp://dx.doi.org/10.1007/s11060-017-2736-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1100349040
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29330749
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Immunological",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bevacizumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Brain Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Glioblastoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Irinotecan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Lomustine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Recurrence, Local",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Jakobsen",
"givenName": "J. N.",
"id": "sg:person.01213020261.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213020261.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Urup",
"givenName": "T.",
"id": "sg:person.0767755164.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767755164.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Grunnet",
"givenName": "K.",
"id": "sg:person.0625037311.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625037311.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Toft",
"givenName": "A.",
"id": "sg:person.01355370407.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355370407.00"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Johansen",
"givenName": "M. D.",
"id": "sg:person.01030124627.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030124627.78"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark",
"Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Poulsen",
"givenName": "S. H.",
"id": "sg:person.016546037435.99",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016546037435.99"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hvidovre Hospital",
"id": "https://www.grid.ac/institutes/grid.411905.8",
"name": [
"Department of Surgical Gastroenterology, Hvidovre Hospital, Ketteg\u00e5rds Alle 30, Hvidovre, Denmark"
],
"type": "Organization"
},
"familyName": "Christensen",
"givenName": "I. J.",
"id": "sg:person.011624566757.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011624566757.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Muhic",
"givenName": "A.",
"id": "sg:person.0655460655.30",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655460655.30"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rigshospitalet",
"id": "https://www.grid.ac/institutes/grid.475435.4",
"name": [
"Department of Radiation Biology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark"
],
"type": "Organization"
},
"familyName": "Poulsen",
"givenName": "H. S.",
"id": "sg:person.01226567303.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226567303.29"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1517/14656566.2011.566558",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003393613"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/neuonc/not226",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012339161"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.molonc.2016.05.005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025103697"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3109/0284186x.2012.681063",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026913192"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1080/02841860802537924",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033303184"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3109/0284186x.2015.1114679",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036696795"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1159/000085575",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041501068"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2008.19.8721",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042965400"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2009.26.3541",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043187529"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(14)70314-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044429820"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11060-011-0565-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046283234",
"https://doi.org/10.1007/s11060-011-0565-x"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa043330",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052112015"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-14-3040",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1063224826"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.1990.8.7.1277",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1078716995"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1707358",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1092706366"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-04",
"datePublishedReg": "2018-04-01",
"description": "The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a comparison to another frequently used combination therapy consisting of irinotecan plus bevacizumab (iri-bev). Seventy patients with recurrent GBM were treated with lomustine 90\u00a0mg/m2 every 6 weeks and bevacizumab 10\u00a0mg/kg every 2 weeks. Toxicity was registered and compared to the toxicity observed in 219 recurrent GBM patients who had previously been treated with irinotecan 125\u00a0mg/m2 and bevacizumab 10\u00a0mg/kg every 2 weeks. The response rate was 37.1% for lom-bev and 30.1% for iri-bev. Median progression-free survival (PFS) was 23 weeks for lom-bev and 21 weeks for iri-bev (p\u2009=\u20090.9). Overall survival (OS) was 37 weeks for lom-bev and 32 weeks for iri-bev (p\u2009=\u20090.5). Lom-bev caused a significantly higher frequency of thrombocytopenia (11.4% grade 3-4) compared to iri-bev (3.5% grade 3-4). Iri-bev patients had more gastrointestinal toxicity with regard to nausea, vomiting, diarrhea, constipation and stomatitis. Within the limitations of the study lom-bev is a well-tolerated treatment for recurrent GBM, although hematological toxicity may be a dose limiting factor. No significant differences between lom-bev and iri-bev were observed with regard to PFS or OS. The differences in toxicity profiles between lom-bev and iri-bev could guide treatment decision in recurrent GBM therapy as efficacy is equal and no predictive factors for efficacy exist.",
"genre": "research_article",
"id": "sg:pub.10.1007/s11060-017-2736-x",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1094205",
"issn": [
"0167-594X",
"1573-7373"
],
"name": "Journal of Neuro-Oncology",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "137"
}
],
"name": "Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients",
"pagination": "439-446",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"1e3ff22d90422d1a26c8609deb615365a16edbcb3c4c48d40a4d653f9d9900e1"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29330749"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8309335"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s11060-017-2736-x"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1100349040"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s11060-017-2736-x",
"https://app.dimensions.ai/details/publication/pub.1100349040"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T09:40",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99839_00000004.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1007%2Fs11060-017-2736-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-017-2736-x'
This table displays all metadata directly associated to this object as RDF triples.
247 TRIPLES
21 PREDICATES
62 URIs
39 LITERALS
27 BLANK NODES